Luminex, a provider of multiplexed solutions, has launched xTAG Cystic Fibrosis 60 Kit v2, a new in-vitro diagnostic test that screens a single blood sample for up to 60 cystic fibrosis-causing genetic mutations in a matter of hours.
The xTAG Cystic Fibrosis 60 Kit v2 can detect up to 60 CFTR gene mutations from a single patient blood sample and allows physicians in choosing to test a patient for the ACMG/ACOG-recommended gene mutations or the entire panel of 60 CFTR gene mutations.
Luminex claimeed tthat xTAG Cystic Fibrosis 60 Kit v2 is easy to use and requires only about one hour of hands-on time to process 48 purified samples and it does not require reflex testing.
The flexible FDA-cleared cystic fibrosis (CF) test features unsurpassed level of gene mutation coverage used to screen potential parents to determine if they are carriers of CF-causing gene mutations, and used for diagnostic screening in newborn and children.
Luminex president and chief executive officer Patrick Balthrop said that the launch of new xTAG Cystic Fibrosis 60 Kit v2 is a great achievement in cystic fibrosis testing and also said that this cleared test has the genetic mutation coverage, featuring mutations found among Caucasians as well as those that are found in other ethnic populations.
The xTAG Cystic Fibrosis 39 Kit v2, which screens a single blood sample for up to 39 cystic fibrosis-causing gene mutations, is available throughout the US, Europe and Canada.